Status | Study |
Not yet recruiting |
Study Name: Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter`s Transformation Requiring Allogeneic Stem Cell Transplantation Condition: Chronic Lymphocytic Leukemia Richter`s Transformation Date: 2017-05-12 Interventions: Biological: Obinutuzumab Obinutuzumab i.v.: 100 mg, 900 mg, 1000 mg |
Not yet recruiting |
Study Name: Study of Blinatumomab in Richter Transformation Condition: Hematopoietic/Lymphoid Cancer Richter's Transformation Date: 2017-04-14 Interventions: Drug: Blinatumomab |
Not yet recruiting |
Study Name: Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome Condition: Richter's Syndrome CLL Date: 2017-04-10 Interventions: Drug: Obinutuzumab, lenalidomide, HDMP |
Not yet recruiting |
Study Name: Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients Condition: Richter Syndrome Date: 2017-04-04 Interventions: Drug: Obinutuzumab 100 mg on d |
Recruiting |
Study Name: A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R for Patients With Richter's Syndrome Condition: Richter Syndrome Date: 2017-02-10 Interventions: Drug: Venetoclax Venetoclax is |
Recruiting |
Study Name: Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170) Condition: Mediastinal Large B-cell Lymphoma Richter Syndrome Date: 2015-10-14 Interventions: Biological: Pembrolizumab IV infusion Other Names: |
Recruiting |
Study Name: Study of Pembrolizumab in Combination With Ublituximab and TGR-1202 in Patients With Relapsed-refractory CLL or Richter's Transformation Condition: Chronic Lymphocytic Leukemia Date: 2015-08-24 Interventions: Drug: Pembrolizumab IV immunot |
Terminated |
Study Name: PNT2258 for Treatment of Patients With Richter's Transformation (Brighton) Condition: Richter's Transformation Date: 2015-02-26 Interventions: Drug: PNT2258 |
Recruiting |
Study Name: Registry of the German CLL Study Group Condition: CLL SLL HCL Date: 2015-02-26 |
Active, not recruiting |
Study Name: ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies Condition: Non-hodgkin Lymphoma Multiple Myeloma Hodgkin Lymphoma Date: 2015-02-07 Interventions: Drug: Acalabrutinib oral |